Please check your internet connection and try again.
# Atorvastatin
## Overview
Atorvastatin is a statin medication that inhibits HMG-CoA reductase, an enzyme crucial for cholesterol synthesis in the liver. This leads to a decrease in low-density lipoprotein (LDL) cholesterol, triglycerides, and an increase in high-density lipoprotein (HDL) cholesterol.
## Primary Indications
* Primary prevention of cardiovascular disease in patients with multiple risk factors.
* Adjunct to diet for the treatment of elevated total cholesterol, LDL-C, triglycerides, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia.
* Treatment of patients with hypertriglyceridemia.
* Treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III).
* Treatment of patients with familial hypercholesterolemia.
* Reduction of risk of stroke and myocardial infarction in patients with multiple risk factors for cardiovascular disease.
## Adult Dosing
* **Hyperlipidemia:** 10 mg to 80 mg once daily.
* **Cardiovascular Risk Reduction:** 10 mg to 80 mg once daily.
* **Maximum Dose:** 80 mg once daily.
## Pediatric Dosing
* **Ages 10 to 17 years (Heterozygous Familial Hypercholesterolemia):** 10 mg once daily, with a maximum dose of 20 mg once daily.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment necessary.
* **Hepatic Impairment:** Use with caution. Avoid in patients with active liver disease. See Contraindications.
## Contraindications
* Active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels.
* Hypersensitivity to any component of this medication.
## Adverse Effects
* **Common:** Diarrhea, nausea, arthralgia, nasopharyngitis, pain in extremity, urinary tract infection.
* **Serious:** Myopathy (including rhabdomyolysis) with renal failure, hepatotoxicity, hyperglycemia, new-onset or worsening of heart failure, immune-mediated necrotizing myopathy (IMNM).
## Key Drug Interactions
* **CYP3A4 Inhibitors (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir):** Increased risk of myopathy and rhabdomyolysis. Avoid coadministration or use lowest atorvastatin dose.
* **Grapefruit Juice:** May increase atorvastatin levels. Limit intake.
* **Cyclosporine, Gemfibrozil, other fibrates, dose-dependent nicotinic acid:** Increased risk of myopathy. Use with caution.
* **Colchicine:** Increased risk of myopathy and rhabdomyolysis. Use with caution.
* **Warfarin:** May increase INR. Monitor INR closely.
* **Oral Contraceptives:** May increase AUC of ethinyl estradiol and norethindrone.
## Monitoring
* **Liver function tests (ALT, AST):** Baseline and periodically thereafter as clinically indicated.
* **Creatine kinase (CK):** If muscle pain, tenderness, or weakness occurs.
* **Lipid panel:** Prior to initiating therapy and at 4-12 week intervals thereafter.
* **HbA1c and blood glucose:** Monitor for hyperglycemia.
## Clinical Pearls
* Initiate therapy with the lowest dose and titrate as needed based on individual lipid response and patient risk factors.
* Patient education on reporting unexplained muscle pain, tenderness, or weakness is crucial.
* Avoid concurrent use with strong CYP3A4 inhibitors when possible.
* Dosing for specific indications like homozygous familial hypercholesterolemia may require consultation with specialist guidelines.
***
**Disclaimer:** This information is intended for healthcare professionals and should not be used as a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines for complete and up-to-date details regarding drug indications, contraindications, warnings, precautions, adverse reactions, and dosing.
